VistaGen Therapeutics, Inc.
VTGN
$0.70
$0.0913.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 161.32% | 13.18% | -17.60% | -33.40% | -54.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 161.32% | 13.18% | -17.60% | -33.40% | -54.28% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 161.32% | 13.18% | -17.60% | -33.40% | -54.28% |
| SG&A Expenses | 8.37% | 10.24% | 2.69% | 7.89% | 21.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.99% | 32.04% | 42.42% | 54.10% | 65.65% |
| Operating Income | -28.85% | -32.29% | -43.58% | -56.33% | -69.51% |
| Income Before Tax | -35.53% | -41.76% | -57.33% | -68.04% | -75.12% |
| Income Tax Expenses | 0.00% | -100.00% | -100.00% | 600.00% | 75.00% |
| Earnings from Continuing Operations | -35.53% | -41.73% | -57.30% | -68.05% | -75.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.53% | -41.73% | -57.30% | -68.05% | -75.12% |
| EBIT | -28.85% | -32.29% | -43.58% | -56.33% | -69.51% |
| EBITDA | -28.84% | -32.29% | -43.62% | -56.45% | -69.71% |
| EPS Basic | -11.01% | -22.71% | -46.44% | -16.40% | 21.67% |
| Normalized Basic EPS | -11.03% | -22.75% | -46.51% | -16.41% | 21.65% |
| EPS Diluted | -11.01% | -22.71% | -46.44% | -16.40% | 21.67% |
| Normalized Diluted EPS | -11.03% | -22.75% | -46.51% | -16.41% | 21.65% |
| Average Basic Shares Outstanding | 23.27% | 15.52% | 7.27% | 24.15% | 59.80% |
| Average Diluted Shares Outstanding | 23.27% | 15.52% | 7.27% | 24.15% | 59.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |